Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | TARS1 | P26639 | 1/20 | 0.51 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 13/20 | 0.48 |
| ▸ | JAK1 | P23458 | 12/20 | 0.47 |
| ▸ | JAK2 | O60674 | 8/20 | 0.45 |
| ▸ | TYK2 | P29597 | 8/20 | 0.45 |
| ▸ | MELK | Q14680 | 1/20 | 0.43 |
| ▸ | AKT2 | P31751 | 1/20 | 0.42 |
| ▸ | BMX | P51813 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30151465 | 0.82 | TARS1 (0.66) | TARS1JAK3JAK1JAK2TYK2 | |
| SCHEMBL24804969 | 0.82 | TARS1 (0.66) | TARS1JAK3JAK1JAK2TYK2 | |
| SCHEMBL15778686 | 0.80 | ESR2 (0.54) | ESR2NR1H2JAK1JAK2 | |
| SCHEMBL21593208 | 0.80 | NR1H2 (0.56) | ESR2TARS1NR1H2JAK3JAK1 | |
| SCHEMBL16245336 | 0.79 | JAK3 (0.61) | JAK3JAK2 | |
| SCHEMBL31662706 | 0.77 | ESR2 (0.53) | ESR2NR1H2JAK1 | |
| SCHEMBL30595975 | 0.77 | JAK1 (0.58) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL4006126 | 0.77 | JAK1 (0.58) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL20775936 | 0.77 | NR1H2 (0.52) | ESR2NR1H2 | |
| SCHEMBL30401624 | 0.77 | NR1H2 (0.52) | ESR2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411420-A1 | PYRROLOPYRIMIDINE DERIVATIVE HAVING ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE INHIBITORY ACTIVITY AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411420-A1 | PYRROLOPYRIMIDINE DERIVATIVE HAVING ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE INHIBITORY ACTIVITY AND USE THEREOF | ENPP1, ENPP3, PPA1 | ESR2 4350/4885TARS1 330/4885NR1H2 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.